ZYBERNO
Stock Report
Updated Sep 1, 2026

NASUS PHARMA LTD. (NSRX)

Healthcare • NYSE

$4.08

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
25.0/100
POOR BUSINESS
NASUS PHARMA LTD. (NSRX) scores 25/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.09x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-223.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

NASUS PHARMA LTD. (NSRX) stock report — Zyberno Score 25/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:4.08
Market Cap:$32.71M

Valuation Multiples (3)

P/B Ratio:11.82x
P/S Ratio:0.03x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$31.59M

Price Action & Momentum (1)

% of 52-Week High:43.0%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:-0.4%
Fundamental Growth Rate (g):0.9%

Margin Analysis (1)

Ebitda Margin:-0.4%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.24x
Quick Ratio:2.24x
Cash Ratio:0.57x

Leverage Analysis (3)

Debt To Equity Ttm:0.09x
Debt-to-Equity Ratio:0.09x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:2,692,000.00
Cash And Cash Equivalents:1,237,000.00
Long Term Debt:$73.00K
Net Debt:-$1.12M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$1.24B
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$4.90M

Bottom Line Performance (3)

-$5.86M
Income Before Tax:$0.00
Ebitda Ttm:-4,904,000.00

Operating Expenses (5)

Operating Expenses:4,904,000.00
R And D Expense:2,237,000.00
Sga Expense:2,667,000.00
Income Tax Expense:$0.00
Interest Expense:-78,000.00

Expense Ratios (3)

R And D To Revenue Percentage:0.2%
Sga To Revenue Percentage:0.2%
Ebitda Margin:-0.4%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$5.00M
Current Assets:$4.86M
Ppe Net:14,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:2,236,000.00
Current Liabilities:2,163,000.00
Long Term Debt:$73.00K
Short Term Debt:$45.00K

Equity & Capital (3)

Equity:$2.77M
Retained Earnings:-$18.52M
Common Stock:22,801,942.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:829,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:447,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$4.92M-$4.93M

Investment Activities (1)

Investing Cash Flow:-$3.01M

Financing Activities (3)

Financing Cash Flow:$8.92M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:8,485,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.73

Revenue & Cash Per Share (2)

Sales Per Share Ttm:154.18
Operating Cash Flow Per Share:-$0.61

Book Value & Capital (2)

Book Value Per Share:$0.35
Cash Per Share:0.15

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:246.80x
Working Capital Turnover Ttm:458.77x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:0.25
Cash Conversion Cycle:-1,998.25
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.4%
Fundamental Growth Rate (g):0.9%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:NSRX
Company Name:NASUS PHARMA LTD.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NYSE
Country:Israel

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:8.01M
Shares Outstanding Basic:8.01M
Shares Outstanding Diluted:8.01M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 06:55:42 UTC
Data Timestamp:2026-08-20T18:24:40.063282
Scroll to Top